Recently, Fosun Pharma's member company Wanbang Biopharmaceuticals (hereinafter referred to as “Wanbang Biopharma”) received the “Certificate of GMP Compliance of a Manufacturer” (hereinafter referred to as “Drug GMP Certificate”) granted by the Health Authority of Netherlands - Health and Youth Care Inspectorate (Pharmaceutical affairs).

The production line in the scope of this “Drug GMP Certificate” is production line IV in the second multifunction formulation building of Wanbang Biopharma; and the main product in this production line is Parecoxib Powder for Solution for Injection (Lyophilized powder). According to the EU's GMP mutual recognition procedure, the production line is in compliance with EU GMP standards.

Fosun Pharma adhered to quality first and strived for excellence. Fosun Pharma has established a production management and service system in line with international standards and encouraged its member companies to promote internationalization. During the Reporting Period, Gland Pharma’s four pharmaceutical manufacturing facilities and three API manufacturing sites all passed audit or certifications in accordance with the drug regulations in the United States, Europe, Brazil and other countries. Furthermore, 1 oral solid formulation, 3 injectable formulations and 5 APIs of Guilin Pharma are prequalified by WHO; Yao Pharma’s oral solid formulation passed GMP inspection from Health Canada and FDA.

In the future, Fosun Pharma will continue to push forward the industrial upgrade of pharmaceutical manufacturing business, further expedite the internationalization process to improve the products market share in global market.